Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patients—A Systematic Review

Shaan Dudani, Sasha Mazzarello, John Hilton, Brian Hutton, Lisa Vandermeer, Ricardo Fernandes, Mohammed F.K. Ibrahim, Stephanie Smith, Habeeb Majeed, Khalid Al-Baimani, Jean Michel Caudrelier, Risa Shorr, Mark Clemons

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

The incidence of leptomeningeal carcinomatosis in breast cancer patients (LC-BC) is increasing. Despite significantly affecting patient quality of life (QoL) and overall survival (OS), little is known about its optimal management. A systematic review of treatment strategies for LC-BC was performed. EMBASE, Ovid Medline, Pubmed, and the Cochrane Central Register of Controlled Trials were searched from 1946 to 2015 for trials reporting on treatments for LC-BC. All treatment modalities and study types were considered. The outcome measures of interest included OS, time to neurologic progression (TTNP), QoL, and treatment toxicity. Of 718 unique citations, 173 studies met the prespecified eligibility criteria. Most were not specific to LC-BC patients. Of 4 identified randomized controlled trials (RCTs), 1 was specific to LC-BC patients and compared systemic therapy and involved-field radiotherapy with or without intrathecal (IT) methotrexate (35 patients), and the remaining 3 had compared different IT chemotherapy regimens (58 of 157 with LC-BC). Of the remaining studies, 19 were nonrandomized interventional studies (225 LC-BC patients), 148 were observational studies (3230 LC-BC patients), and 2 systematic reviews. Minimal prospective data were available on OS, TTNP, QoL, and toxicity. Owing to study heterogeneity, meta-analyses of the endpoint data could not be performed. Limited high-quality evidence exists regarding optimal treatment of LC-BC. The identified studies were heterogeneous and often methodologically poor. The only RCT that specifically assessed the role of IT chemotherapy showed no benefit, and, if anything, harm. Further prospective, tumor-specific trials with improved interstudy methodologic consistency and transparently reported data on OS, TTNP, QoL, and toxicity are urgently needed.

Original languageEnglish
Pages (from-to)456-470
Number of pages15
JournalClinical Breast Cancer
Volume16
Issue number6
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Meningeal Carcinomatosis
Breast Neoplasms
Quality of Life
Nervous System
Survival
Therapeutics
Randomized Controlled Trials
Drug Therapy

Keywords

  • Neurologic progression
  • Overall survival
  • Quality of life
  • Toxicity
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dudani, S., Mazzarello, S., Hilton, J., Hutton, B., Vandermeer, L., Fernandes, R., ... Clemons, M. (2016). Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patients—A Systematic Review. Clinical Breast Cancer, 16(6), 456-470. https://doi.org/10.1016/j.clbc.2016.07.014

Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patients—A Systematic Review. / Dudani, Shaan; Mazzarello, Sasha; Hilton, John; Hutton, Brian; Vandermeer, Lisa; Fernandes, Ricardo; Ibrahim, Mohammed F.K.; Smith, Stephanie; Majeed, Habeeb; Al-Baimani, Khalid; Caudrelier, Jean Michel; Shorr, Risa; Clemons, Mark.

In: Clinical Breast Cancer, Vol. 16, No. 6, 01.12.2016, p. 456-470.

Research output: Contribution to journalReview article

Dudani, S, Mazzarello, S, Hilton, J, Hutton, B, Vandermeer, L, Fernandes, R, Ibrahim, MFK, Smith, S, Majeed, H, Al-Baimani, K, Caudrelier, JM, Shorr, R & Clemons, M 2016, 'Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patients—A Systematic Review', Clinical Breast Cancer, vol. 16, no. 6, pp. 456-470. https://doi.org/10.1016/j.clbc.2016.07.014
Dudani, Shaan ; Mazzarello, Sasha ; Hilton, John ; Hutton, Brian ; Vandermeer, Lisa ; Fernandes, Ricardo ; Ibrahim, Mohammed F.K. ; Smith, Stephanie ; Majeed, Habeeb ; Al-Baimani, Khalid ; Caudrelier, Jean Michel ; Shorr, Risa ; Clemons, Mark. / Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patients—A Systematic Review. In: Clinical Breast Cancer. 2016 ; Vol. 16, No. 6. pp. 456-470.
@article{469d78cbe13f4b99a5d90afc9797bfe3,
title = "Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patients—A Systematic Review",
abstract = "The incidence of leptomeningeal carcinomatosis in breast cancer patients (LC-BC) is increasing. Despite significantly affecting patient quality of life (QoL) and overall survival (OS), little is known about its optimal management. A systematic review of treatment strategies for LC-BC was performed. EMBASE, Ovid Medline, Pubmed, and the Cochrane Central Register of Controlled Trials were searched from 1946 to 2015 for trials reporting on treatments for LC-BC. All treatment modalities and study types were considered. The outcome measures of interest included OS, time to neurologic progression (TTNP), QoL, and treatment toxicity. Of 718 unique citations, 173 studies met the prespecified eligibility criteria. Most were not specific to LC-BC patients. Of 4 identified randomized controlled trials (RCTs), 1 was specific to LC-BC patients and compared systemic therapy and involved-field radiotherapy with or without intrathecal (IT) methotrexate (35 patients), and the remaining 3 had compared different IT chemotherapy regimens (58 of 157 with LC-BC). Of the remaining studies, 19 were nonrandomized interventional studies (225 LC-BC patients), 148 were observational studies (3230 LC-BC patients), and 2 systematic reviews. Minimal prospective data were available on OS, TTNP, QoL, and toxicity. Owing to study heterogeneity, meta-analyses of the endpoint data could not be performed. Limited high-quality evidence exists regarding optimal treatment of LC-BC. The identified studies were heterogeneous and often methodologically poor. The only RCT that specifically assessed the role of IT chemotherapy showed no benefit, and, if anything, harm. Further prospective, tumor-specific trials with improved interstudy methodologic consistency and transparently reported data on OS, TTNP, QoL, and toxicity are urgently needed.",
keywords = "Neurologic progression, Overall survival, Quality of life, Toxicity, Treatment",
author = "Shaan Dudani and Sasha Mazzarello and John Hilton and Brian Hutton and Lisa Vandermeer and Ricardo Fernandes and Ibrahim, {Mohammed F.K.} and Stephanie Smith and Habeeb Majeed and Khalid Al-Baimani and Caudrelier, {Jean Michel} and Risa Shorr and Mark Clemons",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.clbc.2016.07.014",
language = "English",
volume = "16",
pages = "456--470",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patients—A Systematic Review

AU - Dudani, Shaan

AU - Mazzarello, Sasha

AU - Hilton, John

AU - Hutton, Brian

AU - Vandermeer, Lisa

AU - Fernandes, Ricardo

AU - Ibrahim, Mohammed F.K.

AU - Smith, Stephanie

AU - Majeed, Habeeb

AU - Al-Baimani, Khalid

AU - Caudrelier, Jean Michel

AU - Shorr, Risa

AU - Clemons, Mark

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The incidence of leptomeningeal carcinomatosis in breast cancer patients (LC-BC) is increasing. Despite significantly affecting patient quality of life (QoL) and overall survival (OS), little is known about its optimal management. A systematic review of treatment strategies for LC-BC was performed. EMBASE, Ovid Medline, Pubmed, and the Cochrane Central Register of Controlled Trials were searched from 1946 to 2015 for trials reporting on treatments for LC-BC. All treatment modalities and study types were considered. The outcome measures of interest included OS, time to neurologic progression (TTNP), QoL, and treatment toxicity. Of 718 unique citations, 173 studies met the prespecified eligibility criteria. Most were not specific to LC-BC patients. Of 4 identified randomized controlled trials (RCTs), 1 was specific to LC-BC patients and compared systemic therapy and involved-field radiotherapy with or without intrathecal (IT) methotrexate (35 patients), and the remaining 3 had compared different IT chemotherapy regimens (58 of 157 with LC-BC). Of the remaining studies, 19 were nonrandomized interventional studies (225 LC-BC patients), 148 were observational studies (3230 LC-BC patients), and 2 systematic reviews. Minimal prospective data were available on OS, TTNP, QoL, and toxicity. Owing to study heterogeneity, meta-analyses of the endpoint data could not be performed. Limited high-quality evidence exists regarding optimal treatment of LC-BC. The identified studies were heterogeneous and often methodologically poor. The only RCT that specifically assessed the role of IT chemotherapy showed no benefit, and, if anything, harm. Further prospective, tumor-specific trials with improved interstudy methodologic consistency and transparently reported data on OS, TTNP, QoL, and toxicity are urgently needed.

AB - The incidence of leptomeningeal carcinomatosis in breast cancer patients (LC-BC) is increasing. Despite significantly affecting patient quality of life (QoL) and overall survival (OS), little is known about its optimal management. A systematic review of treatment strategies for LC-BC was performed. EMBASE, Ovid Medline, Pubmed, and the Cochrane Central Register of Controlled Trials were searched from 1946 to 2015 for trials reporting on treatments for LC-BC. All treatment modalities and study types were considered. The outcome measures of interest included OS, time to neurologic progression (TTNP), QoL, and treatment toxicity. Of 718 unique citations, 173 studies met the prespecified eligibility criteria. Most were not specific to LC-BC patients. Of 4 identified randomized controlled trials (RCTs), 1 was specific to LC-BC patients and compared systemic therapy and involved-field radiotherapy with or without intrathecal (IT) methotrexate (35 patients), and the remaining 3 had compared different IT chemotherapy regimens (58 of 157 with LC-BC). Of the remaining studies, 19 were nonrandomized interventional studies (225 LC-BC patients), 148 were observational studies (3230 LC-BC patients), and 2 systematic reviews. Minimal prospective data were available on OS, TTNP, QoL, and toxicity. Owing to study heterogeneity, meta-analyses of the endpoint data could not be performed. Limited high-quality evidence exists regarding optimal treatment of LC-BC. The identified studies were heterogeneous and often methodologically poor. The only RCT that specifically assessed the role of IT chemotherapy showed no benefit, and, if anything, harm. Further prospective, tumor-specific trials with improved interstudy methodologic consistency and transparently reported data on OS, TTNP, QoL, and toxicity are urgently needed.

KW - Neurologic progression

KW - Overall survival

KW - Quality of life

KW - Toxicity

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84995612330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995612330&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2016.07.014

DO - 10.1016/j.clbc.2016.07.014

M3 - Review article

VL - 16

SP - 456

EP - 470

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 6

ER -